MCID: FTT001
MIFTS: 61

Fatty Liver Disease

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Metabolic diseases

Aliases & Classifications for Fatty Liver Disease

MalaCards integrated aliases for Fatty Liver Disease:

Name: Fatty Liver Disease 12 42 15
Fatty Liver 74 43 71
Fatty Liver, Alcoholic 43 71
Alcoholic Fatty Liver 12 32
Fatty Change of Liver 12
Fatty Liver Alcoholic 54
Steatosis of Liver 12
Hepatic Lipidosis 12
Steatohepatitis 71

Classifications:



External Ids:

Disease Ontology 12 DOID:9452
ICD9CM 34 571.0
SNOMED-CT 67 50325005 5360002
ICD10 32 K70.0 K76.0
UMLS 71 C0015695 C0015696 C2711227

Summaries for Fatty Liver Disease

MedlinePlus : 42 What is fatty liver disease? Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Fatty liver disease is a condition in which fat builds up in your liver. There are two main types: Nonalcoholic fatty liver disease (NAFLD) Alcoholic fatty liver disease, also called alcoholic steatohepatitis What is nonalcoholic fatty liver disease (NAFLD)? NAFLD is a type of fatty liver disease that is not related to heavy alcohol use. There are two kinds: Simple fatty liver, in which you have fat in your liver but little or no inflammation or liver cell damage. Simple fatty liver typically does not get bad enough to cause liver damage or complications. Nonalcoholic steatohepatitis (NASH), in which you have inflammation and liver cell damage, as well as fat in your liver. Inflammation and liver cell damage can cause fibrosis, or scarring, of the liver. NASH may lead to cirrhosis or liver cancer. What is alcoholic fatty liver disease? Alcoholic fatty liver disease is due to heavy alcohol use. Your liver breaks down most of the alcohol you drink, so it can be removed from your body. But the process of breaking it down can generate harmful substances. These substances can damage liver cells, promote inflammation, and weaken your body's natural defenses. The more alcohol that you drink, the more you damage your liver. Alcoholic fatty liver disease is the earliest stage of alcohol-related liver disease. The next stages are alcoholic hepatitis and cirrhosis. Who is at risk for fatty liver disease? The cause of nonalcoholic fatty liver disease (NAFLD) is unknown. Researchers do know that it is more common in people who Have type 2 diabetes and prediabetes Have obesity Are middle aged or older (although children can also get it) Are Hispanic, followed by non-Hispanic whites. It is less common in African Americans. Have high levels of fats in the blood, such as cholesterol and triglycerides Have high blood pressure Take certain drugs, such as corticosteroids and some cancer drugs Have certain metabolic disorders, including metabolic syndrome Have rapid weight loss Have certain infections, such as hepatitis C Have been exposed to some toxins NAFLD affects about 25 percent of people in the world. As the rates of obesity, type 2 diabetes, and high cholesterol are rising in the United States, so is the rate of NAFLD. NAFLD is the most common chronic liver disorder in the United States. Alcoholic fatty liver disease only happens in people who are heavy drinkers, especially those who have been drinking for a long period of time. The risk is higher for heavy drinkers who are women, have obesity, or have certain genetic mutations. What are the symptoms of fatty liver disease? Both NAFLD and alcoholic fatty liver disease are usually silent diseases with few or no symptoms. If you do have symptoms, you may feel tired or have discomfort in the upper right side of your abdomen. How is fatty liver disease diagnosed? Because there are often no symptoms, it is not easy to find fatty liver disease. Your doctor may suspect that you have it if you get abnormal results on liver tests that you had for other reasons. To make a diagnosis, your doctor will use Your medical history A physical exam Various tests, including blood and imaging tests, and sometimes a biopsy As part of the medical history, your doctor will ask about your alcohol use, to find out whether fat in your liver is a sign of alcoholic fatty liver disease or nonalcoholic fatty liver (NAFLD). He or she will also ask which medicines you take, to try to determine whether a medicine is causing your NAFLD. During the physical exam, your doctor will examine your body and check your weight and height. Your doctor will look for signs of fatty liver disease, such as An enlarged liver Signs of cirrhosis, such as jaundice, a condition that causes your skin and whites of your eyes to turn yellow You will likely have blood tests, including liver function tests and blood count tests. In some cases you may also have imaging tests, like those that check for fat in the liver and the stiffness of your liver. Liver stiffness can mean fibrosis, which is scarring of the liver. In some cases you may also need a liver biopsy to confirm the diagnosis, and to check how bad the liver damage is. What are the treatments for fatty liver disease? Doctors recommend weight loss for nonalcoholic fatty liver. Weight loss can reduce fat in the liver, inflammation, and fibrosis. If your doctor thinks that a certain medicine is the cause of your NAFLD, you should stop taking that medicine. But check with your doctor before stopping the medicine. You may need to get off the medicine gradually, and you might need to switch to another medicine instead. There are no medicines that have been approved to treat NAFLD. Studies are investigating whether a certain diabetes medicine or Vitamin E can help, but more studies are needed. The most important part of treating alcohol-related fatty liver disease is to stop drinking alcohol. If you need help doing that, you may want to see a therapist or participate in an alcohol recovery program. There are also medicines that can help, either by reducing your cravings or making you feel sick if you drink alcohol. Both alcoholic fatty liver disease and one type of nonalcoholic fatty liver disease (nonalcoholic steatohepatitis) can lead to cirrhosis. Doctors can treat the health problems caused by cirrhosis with medicines, operations, and other medical procedures. If the cirrhosis leads to liver failure, you may need a liver transplant. What are some lifestyle changes that can help with fatty liver disease? If you have any of the types of fatty liver disease, there are some lifestyle changes that can help: Eat a healthy diet, limiting salt and sugar, plus eating lots of fruits, vegetables, and whole grains Get vaccinations for hepatitis A and B, the flu and pneumococcal disease. If you get hepatitis A or B along with fatty liver, it is more likely to lead to liver failure. People with chronic liver disease are more likely to get infections, so the other two vaccinations are also important. Get regular exercise, which can help you lose weight and reduce fat in the liver Talk with your doctor before using dietary supplements, such as vitamins, or any complementary or alternative medicines or medical practices. Some herbal remedies can damage your liver.

MalaCards based summary : Fatty Liver Disease, also known as fatty liver, is related to fatty liver disease, nonalcoholic 1 and non-alcoholic steatohepatitis. An important gene associated with Fatty Liver Disease is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are Developmental Biology and Toll-like Receptor Signaling Pathway. The drugs Milk thistle and Losartan have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A lipid storage disease characterized by the accumulation of large vacuoles of triglyceride fat in liver cells via the process of steatosis.

Wikipedia : 74 Fatty liver disease (FLD), also known as hepatic steatosis, is a condition where excess fat builds up in... more...

Related Diseases for Fatty Liver Disease

Diseases related to Fatty Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 746)
# Related Disease Score Top Affiliating Genes
1 fatty liver disease, nonalcoholic 1 35.4 PPARA PNPLA3 LEP INS ADIPOQ
2 non-alcoholic steatohepatitis 34.5 TNF PPARA INS IL6 ADIPOQ
3 non-alcoholic fatty liver disease 33.9 XBP1 TNF SREBF1 PPARA PNPLA3 NR1H3
4 hyperlipidemia, familial combined, 3 33.2 PPARA INS ADIPOQ
5 liver disease 32.6 XBP1 TNF SREBF1 PPARA PNPLA3 NR1H3
6 lipid metabolism disorder 32.3 SREBF1 PPARA LEP IRS1 INS IL6
7 viral hepatitis 32.2 TNF PNPLA3 INS IL6
8 chronic kidney disease 31.9 TNF LEPR LEP INS IL6 ADIPOQ
9 atherosclerosis susceptibility 31.9 TNF PPARA LEP INS IL6 IL1B
10 liver cirrhosis 31.9 MALAT1 LEPR LEP CYP2E1 ADIPOQ
11 arteries, anomalies of 31.8 TNF LEP INS IL6 ADIPOQ
12 polycystic ovary syndrome 31.8 LEP IRS2 IRS1 INS ADIPOQ
13 glucose intolerance 31.8 TNF LEPR LEP IRS1 INS IL6
14 hyperinsulinism 31.7 SREBF1 PPARA LEPR LEP IRS2 IRS1
15 sleep apnea 31.7 TNF LEPR LEP INS IL6 IL1B
16 vascular disease 31.6 TNF LEP INS IL6 ADIPOQ
17 leptin deficiency or dysfunction 31.6 TNF SREBF1 PPARA PNPLA3 LEPR LEP
18 coronary artery anomaly 31.5 TNF IRS1 IL6 IL1B
19 acanthosis nigricans 31.5 LEP INS ADIPOQ
20 choline deficiency disease 31.4 SREBF1 PPARA CYP2E1
21 proteasome-associated autoinflammatory syndrome 1 31.4 TNF PPARA INS IL6 IL1B ADIPOQ
22 end stage renal failure 31.4 TNF LEP IL6 ADIPOQ
23 alcoholic hepatitis 31.3 TNF PNPLA3 IL6 IL1B CYP2E1
24 gastroesophageal reflux 31.3 TNF IL6 IL1B ADIPOQ
25 arteriosclerosis 31.3 PPARA INS IL6 ADIPOQ
26 portal hypertension 31.3 TNF PNPLA3 INS
27 gout 31.3 TNF INS IL6 IL1B
28 apnea, obstructive sleep 31.3 TNF LEP INS IL6 ADIPOQ
29 hyperglycemia 31.2 MALAT1 LEP IRS2 IRS1 INS IL6
30 hypothalamic obesity 31.2 LEPR LEP INS
31 cerebrovascular disease 31.2 TNF LEP INS IL6 ADIPOQ
32 sleep disorder 31.2 TNF LEP INS IL6 ADIPOQ
33 inflammatory bowel disease 31.2 XBP1 TNF PPARA MAPK8 LEP IL6
34 heart disease 31.2 TNF PPARA LEP INS IL6 IL1B
35 insulin-like growth factor i 31.1 LEP IRS2 IRS1 INS
36 abdominal obesity-metabolic syndrome 1 31.1 PPARA LEPR LEP INS ADIPOQ
37 severe pre-eclampsia 31.1 LEPR LEP ADIPOQ
38 retinal vascular disease 31.0 TNF INS IL6 IL1B
39 pulmonary disease, chronic obstructive 31.0 TNF INS IL6 IL1B CYP2E1
40 genetic obesity 31.0 LEPR LEP
41 familial hyperlipidemia 31.0 SREBF1 PPARA LEP INS ADIPOQ
42 gestational diabetes 31.0 TNF LEPR LEP IRS2 IRS1 INS
43 endometritis 30.9 TNF IL6 IL1B
44 acute pancreatitis 30.9 TNF INS IL6 IL1B
45 peripheral nervous system disease 30.9 TNF INS IL6 IL1B
46 nutritional deficiency disease 30.9 LEPR LEP IL6 ADIPOQ
47 overnutrition 30.8 TNF SREBF1 PPARA MAPK8 LEPR LEP
48 protein-energy malnutrition 30.8 TNF LEP IL6
49 inherited metabolic disorder 30.8 TNF SREBF1 PPARA PNPLA3 LEP INS
50 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 30.8 LEP INS ADIPOQ

Comorbidity relations with Fatty Liver Disease via Phenotypic Disease Network (PDN):


Alcoholic Hepatitis Alcoholic Liver Cirrhosis

Graphical network of the top 20 diseases related to Fatty Liver Disease:



Diseases related to Fatty Liver Disease

Symptoms & Phenotypes for Fatty Liver Disease

GenomeRNAi Phenotypes related to Fatty Liver Disease according to GeneCards Suite gene sharing:

26 (show all 18)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.7 IRS2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.7 LEP
3 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.7 XBP1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.7 IRS2 LEP NR1H3 XBP1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.7 XBP1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.7 XBP1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.7 XBP1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.7 IRS2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.7 NR1H3
10 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.7 XBP1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.7 NR1H3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.7 LEP XBP1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.7 IRS2 NR1H3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.7 IRS2 XBP1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.7 NR1H3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.7 IRS2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.7 NR1H3
18 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.7 IRS2

MGI Mouse Phenotypes related to Fatty Liver Disease:

45 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 10.45 ADIPOQ ADIPOR1 ADIPOR2 IL6 INS IRS1
2 homeostasis/metabolism MP:0005376 10.45 ADIPOQ ADIPOR1 ADIPOR2 CYP2E1 IL1B IL6
3 behavior/neurological MP:0005386 10.41 ADIPOQ ADIPOR1 ADIPOR2 CYP2E1 IL6 INS
4 growth/size/body region MP:0005378 10.41 ADIPOQ ADIPOR1 ADIPOR2 CYP2E1 IL1B IL6
5 cardiovascular system MP:0005385 10.4 ADIPOQ CYP2E1 IL1B IL6 INS IRS1
6 cellular MP:0005384 10.39 ADIPOQ ADIPOR1 ADIPOR2 IL6 INS IRS1
7 liver/biliary system MP:0005370 10.36 ADIPOQ ADIPOR1 ADIPOR2 CYP2E1 IL6 INS
8 endocrine/exocrine gland MP:0005379 10.3 ADIPOQ ADIPOR2 IL6 INS IRS1 IRS2
9 hematopoietic system MP:0005397 10.27 ADIPOQ ADIPOR1 IL1B IL6 INS IRS1
10 immune system MP:0005387 10.27 ADIPOQ IL1B IL6 INS IRS1 IRS2
11 mortality/aging MP:0010768 10.27 ADIPOQ CYP2E1 IL1B IL6 INS IRS1
12 integument MP:0010771 10.17 ADIPOQ IL1B IL6 INS IRS2 LEP
13 digestive/alimentary MP:0005381 10.14 IL6 INS LEP LEPR MAPK8 MLXIPL
14 muscle MP:0005369 10.13 ADIPOQ ADIPOR1 IL6 INS IRS1 IRS2
15 nervous system MP:0003631 9.93 ADIPOQ ADIPOR2 IL1B IL6 INS IRS2
16 neoplasm MP:0002006 9.91 ADIPOQ CYP2E1 IL1B IL6 LEP LEPR
17 renal/urinary system MP:0005367 9.61 ADIPOQ IL6 INS IRS2 LEP LEPR
18 skeleton MP:0005390 9.4 ADIPOQ ADIPOR1 ADIPOR2 CYP2E1 IL1B IL6

Drugs & Therapeutics for Fatty Liver Disease

Drugs for Fatty Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 421)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Milk thistle Approved, Experimental, Investigational Phase 4 65666-07-1
2
Losartan Approved Phase 4 114798-26-4 3961
3
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
4
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
5
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
6
Glucagon Approved Phase 4 16941-32-5
7
Rifampicin Approved Phase 4 13292-46-1 5458213 5381226
8
Liraglutide Approved Phase 4 204656-20-2 44147092
9
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
10
Insulin aspart Approved Phase 4 116094-23-6 16132418
11
Insulin detemir Approved Phase 4 169148-63-4 5311023
12
Gliclazide Approved Phase 4 21187-98-4 3475
13
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
14
Propranolol Approved, Investigational Phase 4 525-66-6 4946
15
Ribavirin Approved Phase 4 36791-04-5 37542
16
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
17
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
18
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
19
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
20
Tamoxifen Approved Phase 4 10540-29-1 2733526
21
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
22
Nortriptyline Approved Phase 4 72-69-5 4543
23
Ergotamine Approved Phase 4 113-15-5 8223
24
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
25
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
26
Glimepiride Approved Phase 4 93479-97-1 3476
27
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
28
Phentermine Approved, Illicit Phase 4 122-09-8 4771
29
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
30
Lenvatinib Approved, Investigational Phase 4 417716-92-8
31
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
32
Empagliflozin Approved Phase 4 864070-44-0
33
Alogliptin Approved Phase 4 850649-61-5 11450633
34
Methyltestosterone Approved Phase 4 58-18-4 6010
35
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 6013 10204
36
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
37
Testosterone enanthate Approved Phase 4 315-37-7 9416
38
Dulaglutide Approved, Investigational Phase 4 923950-08-7
39
Metformin Approved Phase 4 657-24-9 14219 4091
40
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
41
Insulin glargine Approved Phase 4 160337-95-1
42
Zinc Approved, Investigational Phase 4 7440-66-6 32051
43
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
44
Saxagliptin Approved Phase 4 361442-04-8 11243969
45
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
46
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
47
Methionine Approved, Nutraceutical Phase 4 63-68-3 6137
48
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
49
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
50
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054

Interventional clinical trials:

(show top 50) (show all 1161)
# Name Status NCT ID Phase Drugs
1 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
2 THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01956825 Phase 4
3 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
4 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
5 Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
6 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
7 Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
8 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
9 Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods Unknown status NCT02210715 Phase 4 Isentress.
10 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
11 Personalized Medicine in HCV Chronic Infection. Endothelial Dysfunction and Subclinical Atheromatosis in Patients With HCV Infection. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02802280 Phase 4
12 Complex Imaging Assessment of Steatosis in Patients Under Treatment With Combination Silimarin, Phyllanthus Niruri and Choline Unknown status NCT02669641 Phase 4
13 Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
14 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
15 PXR-aktivaation Vaikutus Maksan Rasvoittumiseen Completed NCT02329405 Phase 4 Rifampicin;Placebo
16 Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
17 Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM). Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
18 The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease Completed NCT00760513 Phase 4 OMACOR;Placebo oral capsule
19 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study Completed NCT03222206 Phase 4 Salsalate
20 Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
21 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
22 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
23 A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT01006889 Phase 4 Exenatide
24 Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography Completed NCT04038853 Phase 4 1,25-Dihydroxyvitamin D;Placebo
25 Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD) Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
26 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
27 Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes Completed NCT02303730 Phase 4 Exenatide;insulin glargine
28 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
29 The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
30 Effect of Exenatide Treatment on Myocardial Fat Content, Left Ventricular Function, and Vascular Inflammation in Patients With Type 2 Diabetes Mellitus Completed NCT01951651 Phase 4 Exenatide;Glipizide
31 NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
32 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
33 Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Completed NCT03792321 Phase 4 Testosterone Undecanoate;Placebo
34 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Completed NCT02637973 Phase 4 Empagliflozin;Placebo
35 Pioglitazone in Hepatitis C: A Randomized, Double Blind, Placebo-controlled Study Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
36 Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus Completed NCT01432405 Phase 4 Exenatide;Pioglitazone
37 Weight Loss Improves Renal Hemodynamics in Patients With Metabolic Syndrome Completed NCT01356394 Phase 4
38 Biochemical and Echosonographic Impacts Using Siliphos-Selenium-Methionine-Alpha Lipoic Acid + Metformin Versus Metformin in Patients With Fatty Liver and Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
39 Sepsis, Endothelial Function, and Lipids in Critically Ill Patients With Liver Failure (SELLIFA). Randomized Controlled Trial Comparing the Tolerance on Lipids and Safety of Isocaloric Parenteral Nutrition With Enteral Nutrition. Completed NCT00522730 Phase 4
40 Metabolic and Vascular Effects of Silybin in Hypertensive Patients With High One-hour Post-load Plasma Glucose: a Single Arm Pilot Study Completed NCT03538327 Phase 4 Silybin
41 Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone Completed NCT02733679 Phase 4 Metformin;Pioglitazone
42 A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
43 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) to Improve Insulin Secretion and Action in Subjects With Type 2 Diabetes Completed NCT00998335 Phase 4 Long-acting bedtime insulin detemir (Levemir);Insulin detemir and pre-meal insulin aspart.
44 Mechanism of Fatty Acid-induced Impairment of Glucose-stimulated Insulin Secretion - Effect of Buphenyl Completed NCT00533559 Phase 4 sodium phenylbutyrate;Placebo
45 A Prospective, Randomized, Multicentre, Comparative and Open-label Study on Hepatotoxicity of ARIMIDEX Compared With Tamoxifen in Adjuvant Therapy in Postmenopausal Women With Hormone Receptor+ Early Breast Cancer Completed NCT00537771 Phase 4 Anastrozole;Tamoxifen
46 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin Completed NCT02102646 Phase 4 Triptorelin
47 Cupping Therapy and SERKANGABIN Versus Conventional Treatment of Migraine Headache: a Randomized Controlled Trial Completed NCT01476930 Phase 4 conventional migraine drug treatment
48 Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among HIV/HCV-Coinfected Patients Receiving Two Nucleoside Analogs Plus Efavirenz: The Steral Study Completed NCT01900015 Phase 4 Raltegravir;Efavirenz
49 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
50 Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Completed NCT01155206 Phase 4 glucagon

Search NIH Clinical Center for Fatty Liver Disease

Cochrane evidence based reviews: fatty liver

Genetic Tests for Fatty Liver Disease

Anatomical Context for Fatty Liver Disease

MalaCards organs/tissues related to Fatty Liver Disease:

40
Liver, Testes, Kidney, Heart, Bone, Endothelial, Ovary

Publications for Fatty Liver Disease

Articles related to Fatty Liver Disease:

(show top 50) (show all 26001)
# Title Authors PMID Year
1
Adiponectin: a key adipokine in alcoholic fatty liver. 54 61
19491377 2009
2
The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in non alcoholic fatty liver disease. 54 61
19561788 2009
3
Molecular mechanisms of alcoholic fatty liver. 54 61
19032584 2009
4
Adiponectin and alcoholic fatty liver disease. 54 61
18709650 2008
5
Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. 54 61
16108051 2005
6
Adiponectin and alcoholic fatty liver: Is it, after all, about what you eat? 54 61
16116627 2005
7
Role of fatty liver, dietary fatty acid supplements, and obesity in the progression of alcoholic liver disease: introduction and summary of the symposium. 54 61
15670659 2004
8
Clinical features and risk factors of patients with fatty liver in Guangzhou area. 54 61
15040041 2004
9
Relationship between genetic polymorphism of cytochrome P450IIE1 and fatty liver. 54 61
14606109 2003
10
Osteopontin acts as a negative regulator of autophagy accelerating lipid accumulation during the development of nonalcoholic fatty liver disease. 61
31852298 2020
11
Transplantation of brown adipose tissue up-regulates miR-99a to ameliorate liver metabolic disorders in diabetic mice by targeting NOX4. 61
32000567 2020
12
Nuclear magnetic resonance (NMR)-based metabolome profile evaluation in dairy cows with and without displaced abomasum. 61
31858882 2020
13
A phenolic glycoside from Moringa oleifera Lam. improves the carbohydrate and lipid metabolisms through AMPK in db/db mice. 61
31877545 2020
14
Lack of association between early menopause and non-alcoholic fatty liver disease in postmenopausal women. 61
31538495 2020
15
Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin. 61
31556117 2020
16
Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis. 61
31076404 2020
17
Protective effect of metformin against palmitate-induced hepatic cell death. 61
31786336 2020
18
Epidemiology of chronic liver diseases in the USA in the past three decades. 61
31366455 2020
19
Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. 61
31690932 2020
20
CHD is Associated With Higher Grades of NAFLD Predicted by Liver Stiffness. 61
31305280 2020
21
Performance of noninvasive scores for the diagnosis of advanced liver fibrosis in morbidly obese with nonalcoholic fatty liver disease. 61
31464779 2020
22
Crude extract of Camellia oleifera pomace ameliorates the progression of non-alcoholic fatty liver disease via decreasing fat accumulation, insulin resistance and inflammation. 61
31771682 2020
23
Prospective evaluation of non-alcoholic fatty liver disease by elastographic methods of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements. 61
31882273 2020
24
Arterial and liver stiffness in patients with non-alcoholic fatty liver disease: hitting two targets with sodium-glucose co-transporter-2 inhibitors. 61
32011391 2020
25
Nonalcoholic Fatty Liver Disease. 61
32033769 2020
26
Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. 61
32033760 2020
27
Burden of Disease due to Nonalcoholic Fatty Liver Disease. 61
32033757 2020
28
Nutrition and Nonalcoholic Fatty Liver Disease: Current Perspectives. 61
32033765 2020
29
Why Do Lifestyle Recommendations Fail in Most Patients with Nonalcoholic Fatty Liver Disease? 61
32033766 2020
30
Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: The Disease Burden Grows. 61
32033768 2020
31
Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study). 61
31956725 2020
32
Influence of lifestyle factors and staple foods from the Mediterranean diet on non-alcoholic fatty liver disease among older individuals with metabolic syndrome features. 61
31838461 2020
33
Review: Lipid biology in the periparturient dairy cow: contemporary perspectives. 61
32024571 2020
34
Aquaporin-9 is involved in the lipid-lowering activity of the nutraceutical silybin on hepatocytes through modulation of autophagy and lipid droplets composition. 61
31816412 2020
35
Hepatic dysfunction after spinal cord injury: A vicious cycle of central and peripheral pathology? 61
31863731 2020
36
Silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model. 61
31865143 2020
37
San-Huang-Tang protects obesity/diabetes induced NAFLD by upregulating PGC-1α/PEPCK signaling in obese and galr1 knockout mice models. 61
31843573 2020
38
Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient. 61
31764586 2020
39
Natural alkaloid and polyphenol compounds targeting lipid metabolism: Treatment implications in metabolic diseases. 61
31935398 2020
40
Intermediary effect of inflammation on the association between dietary patterns and non-alcoholic fatty liver disease. 61
31809956 2020
41
The effects of hydroalcoholic extract of spinach on prevention and treatment of some metabolic and histologic features in a rat model of nonalcoholic fatty liver disease. 61
31849065 2020
42
Genetic Risk Factors and Disease Modifiers of Nonalcoholic Steatohepatitis. 61
32033763 2020
43
Recruitment and Retention of Patients for Nonalcoholic Steatohepatitis Clinical Trials. 61
32033759 2020
44
Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis. 61
32033758 2020
45
Similarities and Differences Between Nonalcoholic Steatohepatitis and Other Causes of Cirrhosis. 61
32033761 2020
46
Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant. 61
32033762 2020
47
Multitarget and promising role of dihydromyricetin in the treatment of metabolic diseases. 61
31866404 2020
48
How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis. 61
32033764 2020
49
Challenges and opportunities in drug development for nonalcoholic steatohepatitis. 61
31926994 2020
50
Acute Fatty Liver of Pregnancy. 61
31725416 2020

Variations for Fatty Liver Disease

Expression for Fatty Liver Disease

Search GEO for disease gene expression data for Fatty Liver Disease.

Pathways for Fatty Liver Disease

Pathways related to Fatty Liver Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.52 TNF SREBF1 PPARA LEP IRS2 IRS1
2
Show member pathways
13.14 TNF PPARA NR1H3 MAPK8 IL6 IL1B
3
Show member pathways
12.83 XBP1 TNF SREBF1 PPARA NR1H3 MLXIPL
4
Show member pathways
12.73 TNF LEP IRS2 IRS1 INS IL6
5
Show member pathways
12.6 TNF MAPK8 IRS2 IL6 IL1B
6 12.54 SREBF1 IRS2 IRS1 INS ADIPOQ
7
Show member pathways
12.49 XBP1 SREBF1 NR1H3 MLXIPL MAPK8 IRS2
8
Show member pathways
12.47 MAPK8 LEPR LEP IRS2 IRS1 INS
9
Show member pathways
12.43 SREBF1 LEPR LEP IRS2 IRS1 INS
10
Show member pathways
12.35 TNF MAPK8 IL6 IL1B
11
Show member pathways
12.35 TNF INS IL6 IL1B
12
Show member pathways
12.34 MLXIPL INS ADIPOR2 ADIPOR1 ADIPOQ
13 12.32 TNF MAPK8 IL6 IL1B
15 12.26 TNF MAPK8 IL6 IL1B
16 12.25 TNF MAPK8 IL6 IL1B
17
Show member pathways
12.23 TNF MAPK8 IL6 IL1B
18
Show member pathways
12.22 TNF MAPK8 IL6 IL1B
19
Show member pathways
12.22 LEP IRS2 IRS1 INS
20
Show member pathways
12.22 TNF SREBF1 MAPK8 IRS1
21
Show member pathways
12.15 IRS2 IRS1 INS ADIPOR2 ADIPOR1 ADIPOQ
22 12.1 MAPK8 IRS2 IRS1 INS
23
Show member pathways
12.06 MAPK8 IRS2 IRS1 INS IL6
24 12.01 TNF MAPK8 IL6 IL1B
25 12 TNF LEP IL6 IL1B
26
Show member pathways
12 TNF SREBF1 PPARA NR1H3 MLXIPL MAPK8
27 11.96 TNF MAPK8 IL6 IL1B
28 11.89 TNF MAPK8 IL6 IL1B
29
Show member pathways
11.89 TNF MAPK8 IRS2 IRS1 INS ADIPOQ
30 11.82 TNF SREBF1 PPARA PNPLA3 NR1H3 LEP
31 11.8 MAPK8 IL6 IL1B
32 11.78 PPARA NR1H3 ADIPOQ
33 11.77 TNF IL6 IL1B
34 11.75 TNF IL6 IL1B
35 11.74 TNF MAPK8 IL6 IL1B
36 11.71 MAPK8 IRS1 INS
37 11.69 TNF PPARA MAPK8 LEPR LEP IRS2
38
Show member pathways
11.68 TNF IL6 IL1B
39 11.68 TNF IL6 IL1B
40 11.63 TNF IL6 IL1B
41 11.61 IRS2 IRS1 INS
42 11.61 MAPK8 INS IL6
43 11.56 TNF MAPK8 IL6
44 11.56 LEPR LEP IRS2 IRS1
45 11.55 TNF IL6 IL1B
46 11.54 TNF IL6 IL1B
47 11.54 LEPR LEP IRS1 INS
48 11.5 TNF IL6 IL1B
49 11.41 MAPK8 IRS2 IRS1
50 11.39 TNF IL6 IL1B

GO Terms for Fatty Liver Disease

Biological processes related to Fatty Liver Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.24 XBP1 TNF SREBF1 PPARA NR1H3 MLXIPL
2 negative regulation of transcription by RNA polymerase II GO:0000122 10.2 TNF SREBF1 PPARA NR1H3 MLXIPL LEP
3 positive regulation of transcription, DNA-templated GO:0045893 10.16 TNF SREBF1 PPARA NR1H3 MLXIPL IL6
4 positive regulation of gene expression GO:0010628 10.11 TNF MAPK8 INS IL6 IL1B
5 MAPK cascade GO:0000165 10.04 TNF IRS2 IRS1 IL1B
6 positive regulation of cell migration GO:0030335 10.03 XBP1 IRS2 INS IL1B
7 fatty acid metabolic process GO:0006631 9.99 PPARA CYP2E1 ADIPOR2 ADIPOR1
8 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.98 TNF INS IL6 IL1B
9 positive regulation of protein kinase B signaling GO:0051897 9.97 TNF LEP IRS2 IRS1 INS
10 positive regulation of cell proliferation GO:0008284 9.97 XBP1 MLXIPL LEP IRS2 IRS1 INS
11 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.94 TNF LEP IRS2 INS
12 insulin receptor signaling pathway GO:0008286 9.93 SREBF1 IRS2 IRS1 INS
13 response to nutrient GO:0007584 9.9 LEP ADIPOR2 ADIPOQ
14 response to glucose GO:0009749 9.9 SREBF1 IRS2 ADIPOQ
15 response to insulin GO:0032868 9.9 PPARA LEP IRS1
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.89 TNF LEP IL6
17 response to glucocorticoid GO:0051384 9.89 TNF IL6 ADIPOQ
18 regulation of circadian rhythm GO:0042752 9.88 PPARA NR1H3 MAPK8
19 positive regulation of T cell proliferation GO:0042102 9.88 LEP IL6 IL1B
20 positive regulation of interleukin-6 production GO:0032755 9.88 TNF IL6 IL1B
21 regulation of insulin secretion GO:0050796 9.88 TNF SREBF1 LEP IL1B
22 positive regulation of cold-induced thermogenesis GO:0120162 9.88 LEPR LEP ADIPOR2 ADIPOR1 ADIPOQ
23 cellular response to lipopolysaccharide GO:0071222 9.88 XBP1 TNF NR1H3 MAPK8 IL6 IL1B
24 hormone-mediated signaling pathway GO:0009755 9.86 PPARA ADIPOR2 ADIPOR1
25 negative regulation of fat cell differentiation GO:0045599 9.86 TNF IL6 ADIPOQ
26 lipid homeostasis GO:0055088 9.85 PNPLA3 NR1H3 IRS2
27 cellular response to insulin stimulus GO:0032869 9.85 XBP1 SREBF1 IRS2 IRS1 ADIPOQ
28 intracellular receptor signaling pathway GO:0030522 9.84 SREBF1 PPARA NR1H3
29 positive regulation of interleukin-6 secretion GO:2000778 9.83 XBP1 TNF IL1B
30 negative regulation of neurogenesis GO:0050768 9.83 TNF IL6 IL1B
31 positive regulation of interleukin-8 production GO:0032757 9.82 TNF IL1B ADIPOQ
32 lipid metabolic process GO:0006629 9.81 XBP1 SREBF1 PPARA PNPLA3 NR1H3 LEP
33 positive regulation of glial cell proliferation GO:0060252 9.8 TNF IL6 IL1B
34 negative regulation of gluconeogenesis GO:0045721 9.8 LEPR INS ADIPOQ
35 negative regulation of lipid catabolic process GO:0050995 9.79 TNF INS IL1B
36 positive regulation of glycogen biosynthetic process GO:0045725 9.78 IRS2 IRS1 INS
37 positive regulation of cellular protein metabolic process GO:0032270 9.77 NR1H3 INS ADIPOQ
38 fatty acid homeostasis GO:0055089 9.77 XBP1 MLXIPL INS
39 fatty acid oxidation GO:0019395 9.76 ADIPOR2 ADIPOR1 ADIPOQ
40 positive regulation of chemokine biosynthetic process GO:0045080 9.73 TNF IL1B
41 sexual reproduction GO:0019953 9.73 LEPR LEP
42 negative regulation of appetite GO:0032099 9.73 PPARA LEP
43 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.73 PPARA NR1H3 ADIPOQ
44 positive regulation of JAK-STAT cascade GO:0046427 9.73 TNF LEP IL6 ADIPOR1
45 positive regulation of glucose metabolic process GO:0010907 9.72 IRS2 IRS1
46 negative regulation of synaptic transmission GO:0050805 9.72 IL1B ADIPOQ
47 positive regulation of neuroinflammatory response GO:0150078 9.72 TNF IL6 IL1B
48 negative regulation of cholesterol storage GO:0010887 9.71 PPARA NR1H3
49 regulation of fatty acid biosynthetic process GO:0042304 9.71 ADIPOR2 ADIPOR1 ADIPOQ
50 regulation of establishment of endothelial barrier GO:1903140 9.7 TNF IL1B

Molecular functions related to Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.83 XBP1 SREBF1 PPARA NR1H3 MLXIPL
2 signaling receptor activity GO:0038023 9.71 PPARA NR1H3 ADIPOR2 ADIPOR1
3 cytokine activity GO:0005125 9.67 TNF IL6 IL1B ADIPOQ
4 nuclear receptor activity GO:0004879 9.5 SREBF1 PPARA NR1H3
5 adiponectin binding GO:0055100 9.26 ADIPOR2 ADIPOR1
6 adipokinetic hormone receptor activity GO:0097003 9.16 ADIPOR2 ADIPOR1
7 sterol response element binding GO:0032810 8.96 SREBF1 NR1H3
8 insulin receptor binding GO:0005158 8.8 IRS2 IRS1 INS

Sources for Fatty Liver Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....